title: The protective effects of methyl jasmonate against adriamycin--induced hepatic and renal toxicities.
abstract: The aim of the study was to investigate the protective effect of methyl jasmonate (MJ) in adriamycin (ADR) induced hepatic and renal toxicities. 36 BALB/c mice were randomly divided into control, ADR (20 mg/kg), MJ (50 mg/kg) only, MJ (100 mg/kg) only, MJ (50 mg/ kg) + ADR, MJ (100 mg/kg) + ADR groups (n = 6). The 2 doses of MJ was administered for 7 days in MJ only groups, ADR was administered intraperitoneally on the 8th day after pretreatment with the 2 different doses of MJ while ADR was administered on the 8th day only for the ADR only group. The malondialdehyde (MDA), glutathione (GSH), H2O2 generation, superoxide dismutase (SOD), catalase (CAT), glutathione S-transferase (GST), aspartate aminotransferase (AST), alanine aminotransferase (ALT), urea and creatinine in the liver, kidneys and serum samples as applicable were estimated. Tissue MDA, H2O2 generation, and GST activity were markedly elevated while GSH content, CAT and SOD activities were significantly reduced in the tissues when compared to the control (p < 0.05). Pretreatment with MJ ameliorated ADR toxicities, with a significant reduction in serum urea concentration, ALT activity, MDA level, H2O2 generation, GST activity and a significant elevation in GSH content, CAT and SOD activities in the organ tissues. MJ induced significant reduction in MDA level and increase of GSH content in liver and kidney tissues. This study suggests that MJ may play an overall protective effect on ADR-induced toxicities in liver and kidneys and the inhibition of tissue peroxidative damage might contribute to this beneficial effect.
authors.affiliation: Drug Metabolism and Toxicology Research Laboratories, Department of Biochemistry, Faculty of Basic Medical Sciences, (IAMRAT), College of Medicine, University of Ibadan, Ibadan, Nigeria.
authors.forename: A M
authors.initials: AM
authors.lastname: Kosoko
authors.forename: C J
authors.initials: CJ
authors.lastname: Molokwu
authors.forename: E O
authors.initials: EO
authors.lastname: Farombi
authors.forename: O G
authors.initials: OG
authors.lastname: Ademowo
mesh_terms: D000085:Acetates / Q000008:administration & dosage / Q000494:pharmacology; D000818:Animals; D056486:Chemical and Drug Induced Liver Injury / Q000378:metabolism / Q000473:pathology / Q000503:physiopathology / Q000517:prevention & control; D003517:Cyclopentanes / Q000008:administration & dosage / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D004317:Doxorubicin / Q000633:toxicity*; D007668:Kidney / Q000187:drug effects* / Q000473:pathology; D007674:Kidney Diseases / Q000139:chemically induced / Q000378:metabolism / Q000473:pathology / Q000503:physiopathology / Q000517:prevention & control; D007677:Kidney Function Tests / Q000379:methods; D008099:Liver / Q000187:drug effects* / Q000473:pathology; D008111:Liver Function Tests / Q000379:methods; D051379:Mice; D008807:Mice, Inbred BALB C; D023421:Models, Animal; D054883:Oxylipins / Q000008:administration & dosage / Q000494:pharmacology; D020011:Protective Agents / Q000008:administration & dosage / Q000494:pharmacology; D016896:Treatment Outcome
chemical_list: D000085:Acetates; D003517:Cyclopentanes; D054883:Oxylipins; D020011:Protective Agents; D004317:Doxorubicin; C072239:methyl jasmonate